Related references
Note: Only part of the references are listed.IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
Takuya Watanabe et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children
James T. Hayden et al.
CELL CYCLE (2009)
IDH1 Mutations at Residue p.R132 (IDH1R132) Occur Frequently in High-Grade Gliomas But Not in Other Solid Tumors
Fonnet E. Bleeker et al.
HUMAN MUTATION (2009)
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
Mi Ran Kang et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With MGMT Promoter Methylation Status
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
α-Internexin expression identifies 1p19q codeleted gliomas
F. Ducray et al.
NEUROLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma
D. T. W. Jones et al.
ONCOGENE (2009)
Oligodendrogliomas: Molecular Biology and Treatment
Jacolien E. C. Bromberg et al.
ONCOLOGIST (2009)
NOTCH2 Is Neither Rearranged nor Mutated in t(1;19) Positive Oligodendrogliomas
Magdalena Benetkiewicz et al.
PLOS ONE (2009)
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Shimin Zhao et al.
SCIENCE (2009)
Analysis of the IDH1 codon 132 mutation in brain tumors
Joerg Balss et al.
ACTA NEUROPATHOLOGICA (2008)
Anaplastic oligodendroglial tumors: Refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402
Caterina Giannini et al.
BRAIN PATHOLOGY (2008)
Tandem Duplication Producing a Novel Oncogenic BRAF Fusion Gene Defines the Majority of Pilocytic Astrocytomas
David T. W. Jones et al.
CANCER RESEARCH (2008)
Can morphology predict 1p/19q loss in oligodendroglial tumours?
D. Scheie et al.
HISTOPATHOLOGY (2008)
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas
Stefan Pfister et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
Monika E. Hegi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Stem cell-related Self-Renewal signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma
Anastasia Murat et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile
Francois Ducray et al.
MOLECULAR CANCER (2008)
Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas
Ahmed Idbaih et al.
NEURO-ONCOLOGY (2008)
Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri
G. Kaloshi et al.
NEUROLOGY (2008)
Chromosome 1p loss evaluation in anaplastic oligodendrogliomas
Ahmed Idbaih et al.
NEUROPATHOLOGY (2008)
High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas
H. Deshmukh et al.
ONCOGENE (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas
Ahmed Idbaih et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas
K. Ichimura et al.
ONCOGENE (2008)
Combined 1p/19q loss in oligodendroglial tumors: Predictive or prognostic biomarker?
Michael Weller et al.
CLINICAL CANCER RESEARCH (2007)
Loss of NOTCH2 Positively Predicts Survival in Subgroups of Human Glial Brain Tumors
Jean-Louis Boulay et al.
PLOS ONE (2007)
Temozolomide for low-grade gliomas - Predictive impact of 1p/19q loss on response and outcome
G. Kaloshi et al.
NEUROLOGY (2007)
Dynamic history of low-grade gliomas before and after temozolomide treatment
Damien Ricard et al.
ANNALS OF NEUROLOGY (2007)
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide
Olivier L. Chinot et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
MGMT methylation:: A marker of response to temozolomide in low-grade gliomas
Sibille Everhard et al.
ANNALS OF NEUROLOGY (2006)
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma
Robert B. Jenkins et al.
CANCER RESEARCH (2006)
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GICNO study
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment
Mathilde C. M. Kouwenhoven et al.
EUROPEAN JOURNAL OF CANCER (2006)
Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss
Constance A. Griffin et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2006)
Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial
A. Taliansky-Aronov et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors
C. Walker et al.
NEUROLOGY (2006)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
HS Phillips et al.
CANCER CELL (2006)
Two types of chromosome 1p losses with opposite significance in gliomas
A Idbaih et al.
ANNALS OF NEUROLOGY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors
M Möllemann et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas
KB Fallon et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2004)
Glioma classification - A molecular reappraisal
DN Louis et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
